XX-650-23

SKU: orb1703322

Description

XX-650-23 is a small molecule inhibitor that disrupts the CREB-CBP interaction, leading to apoptosis and cell cycle arrest in acute myeloid leukemia (AML) cells. It serves as a valuable research tool for studying AML mechanisms and evaluating therapeutic strategies in both cellular and animal models.

Research Area

Cell Biology, Epigenetics & Chromatin

Key Properties

• CAS Number: 117739-40-9
• MW: 288.3
• Purity: 97.01% (May vary between batches)
• Formula: C₁₈H₁₂N₂O₂
• SMILES: N#CC1=CC=C(C=C1)NC(=O)C2=CC=3C=CC=CC3C=C2O
• Target: Apoptosis,Epigenetic Reader Domain
• Solubility: DMSO:80 mg/mL (277.49 mM);10% DMSO+90% Corn Oil:3.3 mg/mL (11.45 mM)

Bioactivity

• Target IC50:
  AML cells:870 nM-2.3 μM
• In Vivo:
  XX-650-23 (2.3 mg/kg, intravenous injection) extends the survival of AML mouse model (NSG mice) and exhibits no toxicity.
• In Vitro:
  During split Renilla luciferase complementation analysis, XX-650-23 exhibited an IC50 of 3.20 ± 0.43 μM in inhibiting the interaction between CREB and CBP . Following treatment with XX-650-23 (100 pM - 10 μM) for 48 hours, four AML cell lines showed IC50 values ranging from 870 nM to 2.3 μM, defined as a 50% reduction in viable cell count compared to DMSO-treated cells, indicating the inhibition of AML growth by XX-650-23 .

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CREB, Apoptosis, Epigenetic Reader Domain, EpigeneticReaderDomain, XX 650 23, XX65023, XX-650-23

Compound Identifiers

PubChem CID

14978997